Financials in GBp. Standardized financial statements.
A compact view of how Celadon Pharmaceuticals Plc turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Revenue? | £75,000 | £24,000 | £2,000 | £0 | £0 |
| Revenue Growth? | +212.5% | +1100.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | £74,000 | £90,000 | £12,000 | £0 | £0 |
| Gross Profit? | £1,000 | -£66,000 | -£10,000 | £0 | £0 |
| Gross Margin? | +1.3% | -275.0% | -500.0% | 0.0% | 0.0% |
| Operating Expenses? | £5.76M | £12.85M | -£2.72M | £720,647 | £47,452 |
| Operating Income? | -£5.93M | -£5.38M | £2.71M | -£720,647 | -£47,452 |
| EBITDA? | -£6.39M | -£13.61M | -£2.49M | -£660,249 | £0 |
| Income Before Tax | -£7.52M | -£18.12M | -£4.80M | -£1.06M | -£151,697 |
| Income Tax Expense | -£261,000 | -£707,000 | -£13,000 | £0 | £0 |
| Net Income? | -£7.14M | -£17.41M | -£4.63M | -£1.06M | -£151,697 |
| EPS? | £-0.12 | £-0.30 | £-0.10 | £-34.43 | £0.00 |
| Diluted EPS? | £-0.12 | £-0.30 | £-0.10 | £-34.43 | £0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality